Edgewise adds biotech industry adviser to board
BOULDER — Clinical-stage, pre-revenue pharmaceutical company Edgewise Therapeutics Inc. (Nasdaq: EWTX) has appointed biotechnology industry veteran Arlene Morris to its board of directors.
Morris is CEO of Willow Advisors, a life-sciences consulting firm that advises companies on finance, strategy and business development.
“With more than 30 years of exceptional leadership experience in the biotech industry, we are delighted to welcome Arlene to our board,” Edgewise CEO Kevin Koch said in a prepared statement. “Arlene brings invaluable expertise in strategic development and operational excellence, and we are thankful to count her as a valued adviser as we continue to advance our mission of changing the lives of patients and families affected by serious muscle diseases.”
SPONSORED CONTENT
How market participation facilitates the region’s renewable energy use
Platte River Power Authority joined an organized energy market in 2023 and will join another in 2026. Read more about the how these efforts benefit the communities of Estes Park, Fort Collins, Longmont, and Loveland.
EDG-5506, Edgewise’s flagship drug, is an oral drug designed to treat Becker Muscular Dystrophy and Duchenne Muscular Dystrophy, which affect the muscles of the hips, pelvic area, thighs, shoulders and heart.